Oncolytics Biotech Inc. (ONCY)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Wayne F. Pisano M.B.A. | Interim CEO & Chairman of the Board | 224.81k | -- | 1955 |
| Mr. Kirk J. Look C.A., CPA | Chief Financial Officer | 486.54k | -- | -- |
| Dr. Thomas C. Heineman M.D., Ph.D. | Chief Medical Officer | 579.69k | -- | -- |
| Ms. Allison Hagerman P.Eng., P.M.P. | Vice President of Product Development | 352.44k | -- | -- |
| Ms. Amy Goodowitz Levin B.S.N., R.N. | Vice President of Clinical Operations | 389.42k | -- | -- |
| Jon Patton | Director of Investor Relations & Communication | -- | -- | -- |
| Mr. Christophe Degois | Vice President of Business Development | -- | -- | -- |
| Mr. John Mark Lievonen B.B.A., CM, F.C.A., FCPA, LLD, M.B.A. | Consultant | 18.72k | -- | -- |
Oncolytics Biotech Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 28
Description
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Corporate Governance
Upcoming Events
May 7, 2025 at 10:59 AM UTC - May 12, 2025 at 12:00 PM UTC
Oncolytics Biotech Inc. Earnings Date
Recent Events
April 10, 2025 at 12:00 AM UTC
SUPPL: Voluntary supplemental material filed pursuant to Section 11(a) of the Securities Act of 1933 by foreign issuers